Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

91.69EUR
27 Mar 2015
Change (% chg)

€0.31 (+0.34%)
Prev Close
€91.38
Open
€91.19
Day's High
€92.49
Day's Low
€89.88
Volume
3,742,364
Avg. Vol
3,306,694
52-wk High
€94.40
52-wk Low
€69.58

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.64
Market Cap(Mil.): €121,395.50
Shares Outstanding(Mil.): 1,324.14
Dividend: 2.85
Yield (%): 3.11

Financials

  SASY.PA Industry Sector
P/E (TTM): 27.58 40.31 40.78
EPS (TTM): 3.32 -- --
ROI: 5.49 16.86 16.19
ROE: 7.77 17.40 17.04
Search Stocks

Sanofi to launch Toujeo diabetes drug in U.S. on Monday: source

PARIS - French drugmaker Sanofi plans to launch its new Toujeo insulin for diabetics in the United States on Monday, according to a source familiar with the matter.

27 Mar 2015

Sanofi to launch Toujeo diabetes drug in U.S. on Monday -source

PARIS, March 27 - French drugmaker Sanofi plans to launch its new Toujeo insulin for diabetics in the United States on Monday, according to a source familiar with the matter.

27 Mar 2015

BRIEF-Sanofi Pasteur's Gardasil 9 HPV vaccine gets positive opinion from EMA

* Says Gardasil 9, new HPV vaccine from Sanofi Pasteur MSD granted positive opinion by European Ccommittee for Medicinal Products for Human Use

27 Mar 2015

CORRECTED-U.S. FDA again expands usage of Regeneron eye drug Eylea

March 25 - U.S. health regulators on Wednesday approved Regeneron Pharmaceuticals Inc's big-selling eye drug Eylea to treat diabetic retinopathy, the most common diabetic eye disease and a leading cause of blindness in adults.

25 Mar 2015

Bristol, Sanofi and Novartis drugs to shine among 2015 launches

LONDON - Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus sales potential, according to a Thomson Reuters analysis.

23 Mar 2015

UPDATE 1-Bristol, Sanofi and Novartis drugs to shine among 2015 launches

* Up from three potential $1 billion-plus drugs in 2014 (Updates with link to report, paragraph 5)

23 Mar 2015

Bristol, Sanofi and Novartis drugs to shine among 2015 launches

LONDON, March 23 - Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus sales potential, according to a Thomson Reuters analysis.

23 Mar 2015

UPDATE 1-Sanofi test shows lixisenatide doesn't increase cardiovascular risk

PARIS, March 19 - Sanofi's lixisenatide drug for the treatment of type 2 diabetes does not increase cardiovascular risk among high risk patients, the French drugmaker said on Thursday.

19 Mar 2015

BRIEF-Zealand Pharma: Sanofi publishes results for ELIXA outcomes study of Lyxumia

* Says Sanofi has published top-line results from the ELIXA cardiovascular safety outcomes study of Lyxumia (lix-isenatide)

19 Mar 2015

Sanofi says test shows lixisenatide doesn't increase cardiovascular risk

PARIS, March 19 - Drugmaker Sanofi said its lixisenatide drug for the treatment of type 2 diabetes did not increase cardiovascular risk among high risk patients in a study it conducted.

19 Mar 2015

Earnings vs. Estimates

Search Stocks